Recombinant Virus Chikungunya Virus E1 His (C-Term) Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14807
Key Product Details
Source
HEK293
Tag
His (C-Term)
Conjugate
Unconjugated
Applications
SDS-PAGE
Product Specifications
Description
Recombinant CCHFV E1 Envelope protein (NCBI accession #: AIN41199.1, aa 1-415)
Purity
>95% pure by SDS-PAGE
Protein / Peptide Type
Recombinant Protein
Scientific Data Images for Recombinant Virus Chikungunya Virus E1 His (C-Term) Protein
SDS-PAGE: Recombinant Virus Chikungunya Virus E1 His (C-Term) Protein [NBP3-14807]
SDS-Page: Chikungunya Virus E1 Recombinant Protein Antigen [NBP3-14807] - Reducing SDS-PAGE gel showing purified Chikungunya E1 envelope protein running with an expected MW of approximately 60kDa.Formulation, Preparation and Storage
NBP3-14807
Formulation | 20mM Tris-HCl pH 7.8, 210mM NaCl |
Preservative | No Preservative |
Concentration | Please see the vial label for concentration. If unlisted please contact technical services. |
Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Store at 4C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles. |
Background: Chikungunya Virus E1
Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).
References
1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008
2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417
3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368
Long Name
Chikungunya Virus Envelope 1
Alternate Names
CHICKV E1, CHIKV-E1
Additional Chikungunya Virus E1 Products
Product Documents for Recombinant Virus Chikungunya Virus E1 His (C-Term) Protein
Product Specific Notices for Recombinant Virus Chikungunya Virus E1 His (C-Term) Protein
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...